NOAA discovers a new, beautifully weird sea creature

Exceptionally high-quality videos allow scientists to formally introduce a remarkable new comb jelly.

NOAA discovers a new, beautifully weird sea creature
  • Gorgeous simplicity characterizes the comb jelly recently discovered by National Oceanic and Atmospheric Administration Fisheries.
  • The small denizen of the deep was spotted three times beneath the waters off Puerto Rico.
  • Though it's unusual to formally identify an animal strictly based on video observations, the quality of NOAA's video made it possible in a case where there's no better alternative.

Usually, when scientists announce the discovery of a previously unknown animal, they have a specimen of the new arrival in hand. That's not the case, though, with Duobrachium sparksae, an amazing and beautiful ctenophore encountered 3,910 meters beneath the ocean surface about 40 kilometers off the coast of Puerto Rico. No one has met Duobrachium sparksae in person — we know of its existence only through several high-definition videos. ("Ctenophore" is pronounced teen-a-for, by the way.)

Says NOAA Fisheries' Marine Biologist Allen Collins in a NOAA press release, "It's unique because we were able to describe a new species based entirely on high-definition video."

It's also unique because it's such an exquisitely elegant organism.

Meet cute beneath the waves

The first encounter humanity had with the jelly occurred on April 10, 2015, when Deep Discoverer (a remotely operated vehicle or ROV) came across the gelatinous wonder. Fortunately, the ROV sports cameras that were sufficiently high-definition to clearly capture Duobrachium sparksae's fine details.

The animal was first noticed in a video feed by Mike Ford of the shoreside science team working in NOAA's Exploration Command Center far away, outside of Washington, D.C. The ROV was working the Arecibo amphitheater canyon. What Ford saw was, in his words, "a beautiful and unique organism."

Deep Discoverer's cameras produce externally high-resolution images, and are capable of measuring objects as small as a millimeter.The comb jelly's body is about 6 centimeters in size, and its tentacles are about 30 cm long.

While video-based animal identification can be controversial, there was little choice in this case. "We didn't have sample collection capabilities on the ROV at the time," says Collins. "Even if we had the equipment, there would have been very little time to process the animal because gelatinous animals don't preserve very well; ctenophores are even worse than jellyfish in this regard."

Artist's illustration

Credit: Nicholas Bezio/NOAA Office of Ocean Exploration and Research

Describing Duobrachium sparksae

All told, three individuals were observed by the scientists in three separate encounters with the ROV. The image at the top of this article is from the second encounter. The fact that three separate examples were easily spotted leaves scientists hopeful that the creature is not a rarity in the seas.

Ford describes what they saw:

"The ctenophore has long tentacles, and we observed some interesting movement. It moved like a hot air balloon attached to the seafloor on two lines, maintaining a specific altitude above the seafloor. Whether it's attached to the seabed, we're not sure. We did not observe direct attachment during the dive, but it seems like the organism touches the seafloor."

The role that Duobrachium sparksae plays in its ecosystem is not yet understood.

Finding a place in the family

The manner in which light refracted prismatically off the jelly's cilia combs immediately placed it in the ctenophore family as a start.

Collins explains, "We don't have the same microscopes as we would in a lab, but the video can give us enough information to understand the morphology in detail, such as the location of their reproductive parts and other aspects."

"We went," says Ford, "through the historical knowledge of ctenophores and it seemed clear this was a new species and genus as well. We then worked to place it in the tree of life properly."

The videos—the only "specimens" there are of Duobrachium sparksae—are now publicly accessible as part of the Smithsonian National Museum of Natural History Collection.

U.S. Navy controls inventions that claim to change "fabric of reality"

Inventions with revolutionary potential made by a mysterious aerospace engineer for the U.S. Navy come to light.

U.S. Navy ships

Credit: Getty Images
Surprising Science
  • U.S. Navy holds patents for enigmatic inventions by aerospace engineer Dr. Salvatore Pais.
  • Pais came up with technology that can "engineer" reality, devising an ultrafast craft, a fusion reactor, and more.
  • While mostly theoretical at this point, the inventions could transform energy, space, and military sectors.
Keep reading Show less

Why so gassy? Mysterious methane detected on Saturn’s moon

Scientists do not know what is causing the overabundance of the gas.

An impression of NASA's Cassini spacecraft flying through a water plume on the surface of Saturn's moon Enceladus.

Credit: NASA
Surprising Science
  • A new study looked to understand the source of methane on Saturn's moon Enceladus.
  • The scientists used computer models with data from the Cassini spacecraft.
  • The explanation could lie in alien organisms or non-biological processes.
Keep reading Show less

CRISPR therapy cures first genetic disorder inside the body

It marks a breakthrough in using gene editing to treat diseases.

Credit: National Cancer Institute via Unsplash
Technology & Innovation

This article was originally published by our sister site, Freethink.

For the first time, researchers appear to have effectively treated a genetic disorder by directly injecting a CRISPR therapy into patients' bloodstreams — overcoming one of the biggest hurdles to curing diseases with the gene editing technology.

The therapy appears to be astonishingly effective, editing nearly every cell in the liver to stop a disease-causing mutation.

The challenge: CRISPR gives us the ability to correct genetic mutations, and given that such mutations are responsible for more than 6,000 human diseases, the tech has the potential to dramatically improve human health.

One way to use CRISPR to treat diseases is to remove affected cells from a patient, edit out the mutation in the lab, and place the cells back in the body to replicate — that's how one team functionally cured people with the blood disorder sickle cell anemia, editing and then infusing bone marrow cells.

Bone marrow is a special case, though, and many mutations cause disease in organs that are harder to fix.

Another option is to insert the CRISPR system itself into the body so that it can make edits directly in the affected organs (that's only been attempted once, in an ongoing study in which people had a CRISPR therapy injected into their eyes to treat a rare vision disorder).

Injecting a CRISPR therapy right into the bloodstream has been a problem, though, because the therapy has to find the right cells to edit. An inherited mutation will be in the DNA of every cell of your body, but if it only causes disease in the liver, you don't want your therapy being used up in the pancreas or kidneys.

A new CRISPR therapy: Now, researchers from Intellia Therapeutics and Regeneron Pharmaceuticals have demonstrated for the first time that a CRISPR therapy delivered into the bloodstream can travel to desired tissues to make edits.

We can overcome one of the biggest challenges with applying CRISPR clinically.

—JENNIFER DOUDNA

"This is a major milestone for patients," Jennifer Doudna, co-developer of CRISPR, who wasn't involved in the trial, told NPR.

"While these are early data, they show us that we can overcome one of the biggest challenges with applying CRISPR clinically so far, which is being able to deliver it systemically and get it to the right place," she continued.

What they did: During a phase 1 clinical trial, Intellia researchers injected a CRISPR therapy dubbed NTLA-2001 into the bloodstreams of six people with a rare, potentially fatal genetic disorder called transthyretin amyloidosis.

The livers of people with transthyretin amyloidosis produce a destructive protein, and the CRISPR therapy was designed to target the gene that makes the protein and halt its production. After just one injection of NTLA-2001, the three patients given a higher dose saw their levels of the protein drop by 80% to 96%.

A better option: The CRISPR therapy produced only mild adverse effects and did lower the protein levels, but we don't know yet if the effect will be permanent. It'll also be a few months before we know if the therapy can alleviate the symptoms of transthyretin amyloidosis.

This is a wonderful day for the future of gene-editing as a medicine.

—FYODOR URNOV

If everything goes as hoped, though, NTLA-2001 could one day offer a better treatment option for transthyretin amyloidosis than a currently approved medication, patisiran, which only reduces toxic protein levels by 81% and must be injected regularly.

Looking ahead: Even more exciting than NTLA-2001's potential impact on transthyretin amyloidosis, though, is the knowledge that we may be able to use CRISPR injections to treat other genetic disorders that are difficult to target directly, such as heart or brain diseases.

"This is a wonderful day for the future of gene-editing as a medicine," Fyodor Urnov, a UC Berkeley professor of genetics, who wasn't involved in the trial, told NPR. "We as a species are watching this remarkable new show called: our gene-edited future."

Quantcast